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Background. Electroconvulsive therapy (ECT) is widely applied to treat severe depression resistant to standard treat-
ment. Results from previous studies comparing the cost-effectiveness of this technique with treatment alternatives
such as repetitive transcranial magnetic stimulation (rTMS) are conﬂicting.
Method. We conducted a cost-effectiveness analysis comparing ECT alone, rTMS alone and rTMS followed by ECT
when rTMS fails under the perspective of the Spanish National Health Service. The analysis is based on a Markov
model which simulates the costs and health outcomes of individuals treated under these alternatives over a 12-month
period. Data to populate this model were extracted and synthesized from a series of randomized controlled trials and
other studies that have compared these techniques on the patient group of interest. We measure effectiveness using qual-
ity-adjusted life years (QALYs) and characterize the uncertainty using probabilistic sensitivity analyses.
Results. ECT alone was found to be less costly and more effective than rTMS alone, while the strategy of providing
rTMS followed by ECT when rTMS fails is the most expensive and effective option. The incremental cost per QALY
gained of this latter strategy was found to be above the reference willingness-to-pay threshold used in these types of
studies in Spain and other countries. The probability that ECT alone is the most cost-effective alternative was estimated
to be around 70%.
Conclusions. ECT is likely to be the most cost-effective option in the treatment of resistant severe depression for a will-
ingness to pay of €30 000 per QALY.
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Introduction
Electroconvulsive therapy (ECT) is a technique widely
applied to treat severe depression in patients who do
not respond to treatment with medication or psycho-
logical therapies. This technique induces a controlled
generalized seizure in the central nervous system
through electrical stimulation. Although there is
variation across countries and hospitals, ECT is now
generally performed under anaesthesia, with myore-
laxation, artiﬁcial ventilation, and using computerized
devices to achieve an adequate seizure, safely and
effectively, minimizing potential adverse events. ECT
is, however, still associated with some side-effects
such as amnesia (temporary or permanent), confusion,
headache, and nausea (see reviews by Carney et al.
2003; Dunne & McLoughlin, 2012). Repetitive trans-
cranial magnetic stimulation (rTMS) is an alternative
technique more recently introduced which has the ad-
vantage of not requiring anaesthesia, it stimulates the
brain non-convulsively and the reported side-effects
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have been limited to moderate headaches. However,
some studies have found that rTMS is not as effective
as ECT in the treatment of severe depression (Berlim
et al. 2013).
In the widespread context of scarce healthcare
resources, there is a need to compare healthcare strate-
gies, not only in terms of clinical effectiveness, but also
in terms of their economic consequences. This compari-
son provides decision makers with additional evidence
to assist them in making choices between competing
alternatives within budget constraints.
The cost-effectiveness of ECT v. rTMS has been con-
sidered in previous published studies but with conﬂict-
ing results. Kozel et al. (2004) used a decision model to
evaluate the cost-effectiveness of ECT alone, rTMS
alone and rTMS followed by ECT when rTMS failed.
They concluded that rTMS alone offered a considerable
economic beneﬁt on healthcare and patient costs over
ECT alone, and that rTMS followed by ECT was the
most effective and least costly option. Knapp et al.
(2008) conducted an economic evaluation alongside a
more recent clinical trial comparing patients randomly
treated with ECT and rTMS with a 6-month follow-up
(for further details on the trial see Eranti et al. 2007).
Contrary to the results found in Kozel et al. (2004),
they found that rTMS had a very low probability of
being cost-effective compared with ECT; rTMS was
found not to be as effective as ECT and there were gen-
erally no differences on healthcare costs, while infor-
mal care costs were higher with rTMS.
The aim of this study is to develop a decision ana-
lytical model of the cost-effectiveness of ECT v. rTMS
for treatment-resistant severe depression using all rel-
evant studies with best available quality (NICE,
2013). We do this by synthesizing all available infor-
mation into a decision model that combines data
from, alongside other sources, the series of randomized
controlled trials that have compared ECT and rTMS in
the treatment of resistant severe depression.
Method
We conducted an economic evaluation comparing ECT
with rTMS for severe depression in patients who do
not respond to pharmacological and psychological
therapies. In particular, and following the study pub-
lished by Kozel et al. in 2004, we compared three alter-
natives: ECT alone, rTMS alone and rTMS followed by
ECT when rTMS fails. The characteristics of the popu-
lation of interest for this evaluation are similar to the
sample characteristics deﬁned in a recent systematic re-
view with meta-analysis of RCTs comparing ECT v.
rTMS (Berlim et al. 2013), i.e. subjects aged between
18 and 75 years with a diagnosis of (unipolar or bi-
polar) major depression starting treatment with ECT
or rTMS without new antidepressant therapy. The pri-
mary reason for administration of ECT or rTMS treat-
ment in these studies was resistance to standard
treatment or refractoriness of depression.
The analysis took the perspective of the National
Health Service (NHS) in Spain, i.e. we considered the
costs that are incurred by the Spanish NHS.
Effectiveness was measured using quality-adjusted
life years (QALYs). QALYs are a measure of health-
related quality of life (QoL) that combines information
on QoL and length of life and that is widely recom-
mended in economic evaluations to facilitate com-
parable decisions about resource allocation across dif-
ferent health conditions (NICE, 2013). QoL values
for depression have been estimated in a number of stu-
dies in the literature (see review by Peasgood et al.
2012).
The cost-effectiveness analysis was based on a
Markov model which deﬁnes the health and treatment
states and possible consequences of the interventions.
The prognosis of patients was modelled based on a
set of possible transitions between these states over a
series of discrete time periods (each cycle was
deﬁned as 15 days in our model, i.e. patients might
transit from one state to another every 15 days). This
model structure is more ﬂexible than other model alter-
natives, such as decision trees, and allows us to easily
incorporate potential events such as relapses and
recurrences. Similarly to other economic analyses of
depression treatment (e.g. Greenhalgh et al. 2005), we
considered a time-frame of 12 months for the analysis,
as valid data for longer periods are not readily avail-
able; hence discounting was not undertaken.
Cost-effectiveness was summarized by the in-
cremental cost-effectiveness ratio (ICER), which is
deﬁned as the incremental cost divided by the in-
cremental effectiveness of two competing alternatives
(Drummond et al. 2005). The ICER represents the ad-
ditional cost of one unit of outcome gained (in our
case QALY) by a healthcare intervention or strategy,
when compared to the next best alternative. This out-
come is then compared with the decision maker’s
willingness-to-pay threshold per unit of effectiveness
in order to draw conclusions about whether or not
the intervention is viewed as cost-effective. In Spain
there is not an explicit willingness-to-pay threshold,
but a reference value has been estimated as €30 000/
QALY (Sacristán et al. 2002).
We undertook a deterministic analysis using the
mean values for each model parameter, and developed
a probabilistic sensitivity analysis in order to character-
ize the uncertainty in the model results. We repre-
sented graphically the uncertainty in the results by
the means of the cost-effectiveness plane and the
cost-effectiveness acceptability curves (CEACs).
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CEACs indicate the probability that an intervention is
cost-effective for different values of willingness to
pay per effectiveness unit.
Model structure
Fig. 1 shows the structure of the Markov model. The
following speciﬁc terms are used to describe our
model: response, remission, relapse, and recurrence.
The deﬁnitions of these outcomes were based on
those used on the studies identiﬁed and are deﬁned
as follows: patients are deemed to have responded to
acute treatment when they experience a 550–60%
(depending on the study) decrease from baseline to
end of acute treatment on the Hamilton Depression
Rating Scale (HAMD); the remission criterion requires
a HAMD score of 48 after a period of 6 months; re-
lapse is deﬁned as a return of depressive symptoma-
tology with a HAMD score of516 during the
continuation treatment; while we deﬁned recurrence
when the patient returns to a HAMD score of516
after having remitted.
In our model a patient suffering from an acute epi-
sode of severe depression, which fails to improve
after medication and/or psychological therapies,
receives acute treatment for a 2-week period using
ECT in the ECT-alone group or rTMS in the rTMS
and rTMS + ECT groups. After the acute treatment,
the patient might respond and will then move into
the continuation treatment state with rTMS or ECT
depending on the group, or the patient might suffer
an adverse event that leads to discontinuation of the
therapy or might not respond to treatment. In the
last two cases, the patient will return to a health state
of severe depression since their condition would have
not improved. Note that we do not explicitly consider
the impact on the patients of the possible adverse
events separately, but we implicitly account for them
by considering that patients suffering these side-effects
will discontinue treatment and return to the severe de-
pression state, which is related to a lower QoL and
higher healthcare costs.
If the patient responds to the acute treatment, the
continuation treatment might last for up to 6 months
(with a minimum of 4 months for which we included
a series of so-called ‘tunnel-states’ in the Markov
model – not shown in Fig. 1). Tunnel states are ad-
ditional states that facilitate accounting for time-
dependency in a Markov model (Briggs et al. 2006).
In our case, the minimum time individuals receive con-
tinuation treatment before they are classiﬁed, or not, as
in remission is 4 months, but the cycle length of the
model is of 15 days. Therefore, the tunnel states
allow us to force individuals to stay in the continuation
treatment state during at least 4 months before moving
to the remission or depression states. However, at any
time during the continuation treatment the patient
might experience an adverse event or might relapse.
In the latter case the patient will be provided with
acute treatment again. After continuation treatment,
the patient might be classiﬁed as in remission or
might not remit and thus move to a health state of
moderate depression. Those who are in remission
might quit or continue with treatment and, in any
case, the patient might experience a relapse and
move to the severe depression state. In the case of
the strategy deﬁned as ‘rTMS followed by ECT when
rTMS fails’, if patients do not respond or do not
remit, or if they experience an adverse effect or a
re-occurrence, they will consequently be treated with
Stable with Tx
Continuation
Tx
Death
Stable without Tx
Severe depression
Acute Tx
Go to Acute treatment 
with ECT for "rTMS 
followed by ECT"
Relapse
Response
No response + 
adverse event
Remission
DroppingTx + adverse event
RecurrenceNo remission + adverse event
Suicide + death for other causes (all dashed lines)
Moderate depression
Recurrence
Fig. 1. Markov model structure. Tx, treatment; ECT, Electroconvulsive therapy; rTMS, repetitive transcranial magnetic
stimulation.
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ECT as second-line treatment. At any given time and
health state, there is a risk of mortality due to suicide
or due to other reasons.
Data
The data required to populate the model fall within
four general types: transition probabilities between
states for ECT and rTMS (and associated relative
risks); use of healthcare resources for each health
state and intervention; the unit costs of healthcare
resources; and utility weights for the health states iden-
tiﬁed in the model to calculate QALYs.
We conducted a series of structured literature
reviews using the following data sources: OvidSP,
Medline, EMBASE, and the databases DARE,
NHSEED and HTA at the Centre for Reviews and
Dissemination at the University of York, with the pri-
mary aim of identifying RCTs comparing both inter-
ventions on the patient group of interest, as well as
guidelines of clinical practice for each intervention
and sources for unit costs and QALY weights. The
structured literature reviews were complemented
with manual searches in reference lists of identiﬁed
sources, as well as Google searches and discussion
with clinical experts in the ﬁeld.
Transition probabilities and relative risks
There are a number of RCTs which have compared
ECT v. rTMS in treatment-resistant depression. A re-
cent systematic review with meta-analysis identiﬁed
seven RCTs (Berlim et al. 2013). Of the seven random-
ized trials on rTMS v. ECT for depression resistant
to standard treatment included in this meta-analysis,
six were selected for our economic evaluation
(Grunhaus et al. 2000, 2003; Janicak et al. 2002; Rosa
et al. 2006; Eranti et al. 2007; Keshtkar et al. 2011). We
did not include information from one study
(Pridmore et al. 2000) because it did not report any of
the parameters of interest for our model as indicated
in the model structure; but we included an additional
study reporting long-term outcomes (Dannon et al.
2002).
With respect to the ﬁndings of the included trials,
Janicak et al. (2002), Grunhaus et al. (2003), and Rosa
et al. (2006) found no differences on response rate be-
tween ECT and rTMS, while Eranti et al. (2007) and
Grunhaus et al. (2000) found a signiﬁcantly higher
probability of response on patients treated with ECT.
Keshtkar et al. (2011) also found better efﬁcacy with
ECT than rTMS but did not report a response or re-
mission rate. Dannon et al. (2002) reported similar
probabilities of longer-term remission for both techni-
ques, and Eranti et al. (2007) also reported similar
probabilities of remission in the patient who
responded to initial acute treatment. Rosa et al. (2006)
reported higher rates of discontinuation of therapy
due to adverse events with ECT than with rTMS
while this probability was the same in other studies
(Janicak et al. 2002; Eranti et al. 2007; Keshtkar et al.
2011).
Information required for some parameters were
not available from these comparative studies, and
thus were extracted from studies based on ECT as-
suming the same value for rTMS. These parameters
were: suicide rates for individuals treated with ECT
extracted from Hunt et al. (2011); re-occurrence of de-
pression probability with and without treatment
which was based on a study by Sackeim et al.
(2001) focused on patients on continuation treatment
after ECT; and the probability of quitting treatment
during stabilization which was extracted from
Dannon et al. (2002) (who did not differentiate by
treatment arm for this parameter) and Sackeim et al.
(2001).
For those parameters for which information was
available on more than one study we conducted
meta-analyses using ﬁxed effect models to synthesize
the information. As previously mentioned, the cycle
length in the Markov model was 15 days. Therefore,
transition probabilities and relative risks which were
reported for a different time period were converted
to instantaneous rates assuming a ﬁxed rate and then
probabilities for a 15-day period (see Table 1).
Healthcare resource use and unit costs
Information of the use of healthcare resources for each
health state and intervention were obtained from
publications on current clinical practice in Spain
(Bertolín-Guillén et al. 2006; Martínez-Amorós et al.
2012), from the description of resources recorded
alongside a clinical trial (Knapp et al. 2008), and by
communication with clinical experts (see Table 2).
The number of sessions during a course of ECT and
rTMS during acute treatment varies in clinical practice
as well as in the trial protocols used in the studies iden-
tiﬁed. In the base case of our analysis we considered a
mean of two ECT sessions per week and a mean of ﬁve
rTMS sessions per week over the 2 weeks of acute
treatment for each technique. This is reduced to one
session every 15 days for ECT and two sessions
every 15 days for rTMS during the continuation treat-
ment. Once the patient has remitted he/she might con-
tinue with therapy to avoid re-occurrences; in those
cases we consider one session every 2 months for
both ECT and rTMS.
Over and above ECT and rTMS sessions, other
healthcare resources used during the period of
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continuation of treatment were estimated based on the
data collected in Knapp et al. (2008) on the number
of inpatient stays, outpatient visits, GP visits and
Accident & Emergency (A&E) attendances in each
arm. The level of utilization of healthcare services in
the depression and remitter states were extracted
from studies detailing the use of healthcare consulta-
tions due to depression considering different states:
stable, in-hospital with depression, out-of-hospital
with depression (Pinto-Meza et al. 2008; Gothefors
et al. 2010; Tafalla et al. 2010). The probability of hospi-
talization in this group of patients was estimated from
Knapp et al. (2008). Based on communication with
medical experts, we included an assumption on the
number of A&E visits in the remission and depression
periods.
Whenever available, unit costs were measured
by the average cost of the Autonomous Communities
in Spain that publish the ofﬁcial tariffs of the services
of interest and were captured in the eSalud database
(www.oblikue.com). We also used national data
published on the Ministry of Health Statistics website
(www.msn.pestadisitico.es). The unit costs of ECT
was obtained from a cost analysis performed by the
Hospital Universitario de Canarias detailing the
healthcare resources (staff, material, equipment, tests,
medication) used during an ECT session, to which
we then applied national unit costs when those were
available. Costs were expressed in 2013 euros (€);
cost estimates reported for earlier years were inﬂated
using the Consumer Price Index published at the
National Institute of Statistics (INE; www.ine.es).
QoL estimates
Bennett et al. (2000) estimated the value of the
health-related QoL of patients with depression using
a disease-speciﬁc utility measure (McSad) and by
Table 1. Transition probabilities and relative risks (15-day cycle)
Value S.E. Sources
Probability
distribution
Transition probabilities (15-day cycle)
Response (ECT) 0.3722 0.0521 Eranti et al. (2007), Rosa et al. (2006),
Grunhaus et al. (2003), Janicak et al.
(2002), Grunhaus et al. (2000)
Beta
Adverse effect leading to
discontinuing acute treatment (ECT)
0.0549 0.0239 Janicak et al. (2002), Rosa et al. (2006),
Eranti et al. (2007), Keshtkar et al.
(2011)
Beta
Relapse (ECT) 0.0184 0.0301 Dannon et al. (2002) Beta
Remission (at 4th month – ECT) 0.3700 0.1394 Eranti et al. (2007) Beta
Remission (after 4th month – ECT) 0.0561 0.0664 Eranti et al. (2007) Beta
Drop-out treatment after remission 0.0090 0.0084 Sackeim et al. (2001), Dannon et al.
(2002)
Beta
Recurrence with treatment 0.0405 0.0411 Sackeim et al. (2001) Beta
Recurrence without treatment 0.1416 0.0697 Sackeim et al. (2001) Beta
Suicide 0.00003 0.00008 Hunt et al. (2011) Beta
Death (other causes) 0.0002 – INE
Value Variance Ln (RR) Sources
Probability
distribution
Relative risks, rTMS v. ECT
Response 0.7012 0.2384 Eranti et al. (2007), Rosa et al. (2006),
Grunhaus et al. (2003), Janicak et al.
(2002), Grunhaus et al. (2000)
Log normal
Adverse effect 0.8006 0.5843 Janicak et al. (2002), Rosa et al. (2006),
Eranti et al. (2007), Keshtkar et al.
(2011)
Log normal
Relapse 0.9474 0.4024 Dannon et al. (2002) Log normal
Remission 1.0000 0.5670 Eranti et al. (2007) Log normal
S.E., Standard error; ECT, electroconvulsive therapy; INE, Institute of National Statistics (in Spanish); RR, relative risk; rTMS,
repetitive transcranial magnetic stimulation.
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Table 2. Resource use (15-day cycle), unit costs and QALY weights
Value S.E. Sources
Probability
distribution
Resource use (15-day cycle)
Acute Tx Number of sessions (ECT) 4.00 0.80 Bertolín-Guillén et al. (2006),
Martínez-Amorós et al. (2012)
Gamma
Number of sessions (rTMS) 10.00 2.00 Knapp et al. (2008) Gamma
Continuation
Tx
Number of sessions (ECT) 1.00 0.50 Martínez-Amorós et al. (2012) Gamma
Number of sessions (rTMS) 2.00 1.00 Expert opinion Gamma
In-hospital days (ECT) 0.43 0.09 Knapp et al. (2008) Gamma
In-hospital days (rTMS) 0.97 0.19 Knapp et al. (2008) Gamma
Psychiatrist visits (ECT) 0.05 0.01 Knapp et al. (2008) Gamma
Psychiatrist visits (rTMS) 0.39 0.08 Knapp et al. (2008) Gamma
A&E visits (ECT) 0.02 0.003 Knapp et al. (2008) Gamma
A&E visits (rTMS) 0.02 0.004 Knapp et al. (2008) Gamma
GP visits (ECT) 0.97 0.19 Knapp et al. (2008) Gamma
GP visits (rTMS) 2.27 0.45 Knapp et al. (2008) Gamma
Stable Number of sessions (ECT) 0.25 0.05 Martínez-Amorós et al. (2012) Gamma
Number of sessions (rTMS) 0.25 0.05 Expert opinion Gamma
Psychiatrist visits 0.27 0.05 Pinto-Meza et al. (2008) Gamma
A&E visits 0.25 0.05 Expert opinion Gamma
GP visits 0.67 0.13 Pinto-Meza et al. (2008) Gamma
Clinical tests 0.21 0.04 Gothefors et al. (2010) Gamma
Depression
outpatient
Psychiatrist visits 0.54 0.11 Pinto-Meza et al. (2008) Gamma
A&E visits 0.50 0.10 Expert opinion Gamma
GP visits 1.34 0.27 Pinto-Meza et al. (2008) Gamma
Clinical tests 0.21 0.04 Gothefors et al. (2010) Gamma
Depression
inpatient
In-hospital (days) 7.48 1.50 Tafalla et al. (2010) Gamma
Psychiatrist visits 0.27 0.05 Pinto-Meza et al. (2008) Gamma
A&E visits 0.25 0.05 Expert opinion Gamma
GP visits 0.67 0.13 Pinto-Meza et al. (2008) Gamma
Clinical tests 0.21 0.04 Gothefors et al. (2010) Gamma
Hospitalization probability 0.13 0.03 Knapp et al. (2008) Gamma
Unit costs rTMS session €319 €64 eSalud Normal
ECT session €737 €147 HUC/eSalud Normal
In-hospital day €369 €74 pestadístico Normal
Psychiatrist visit €44 €9 eSalud Normal
A&E visit €167 €33 eSalud Normal
GP visit €21 €4 eSalud Normal
Clinical test €12 €2 eSalud Normal
Using McSad (Bennett et al. 2000) Using EQ-5D (Mann et al. 2009) Probability
distributionValue S.E. Value S.E.
Quality of life weights
Acute Tx 0.090 0.020 0.519 0.290 Beta
Continuation
Tx
0.590 0.018 0.645 0.230 Beta
Stable 0.790 0.023 0.759 0.250 Beta
Moderate
depression
0.320 0.013 0.558 0.013 Beta
Severe
depression
0.090 0.020 0.337 0.020 Beta
QALY, Quality adjusted life year; S.E., standard error; Tx, Treatment; ECT, electroconvulsive therapy; rTMS, repetitive
transcranial magnetic stimulation; A&E, accident and emergency; GP, general practitioner; HUC, Hospital Universitario de
Canarias; pestadítico, Ministry of Health Statistics website.
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interviewing 105 patients with recent episodes of de-
pression. McSad is a depression state classiﬁcation
system which consists of six dimensions: emotion, self-
appraisal, cognition, physiology, behaviour, and role
function, with four possible levels each. These data
have been recently used in a cost-effectiveness analysis
for the Health Technology Assessment programme on
depression in UK (Greenhalgh et al. 2005). We used
these data to estimate the QoL of individuals in each
health state considered in our model (see Table 2).
We also applied a different set of QoL values estimated
in a study by Mann et al. (2009) on 114 patients with
major depressive disorder participating in a RCT in
the UK. Mann et al. used both the EQ-5D (www.euro
qol.org) and SF-6D (www.shef.ac.uk/scharr/sections/
heds/mvh/sf-6d), questionnaires which apply generic
dimensions of health (i.e. mobility, self-care, usual
activities, anxiety/depression, etc.) to characterize
health-related QoL. They found that EQ-5D was
more sensitive and able to capture changes in the
participants, and therefore we considered the values
estimated using EQ-5D in this study (Table 2). Not
surprisingly, the disease-speciﬁc McSad instrument,
which focuses on dimensions related to mental health,
yielded lower QoL values in depression patients than
the EQ-5D, which it is generally considered the pre-
ferred QoL instrument in economic evaluations
(NICE, 2013), but that includes some dimensions not
necessarily relevant for depressed patients. We report
the cost-effectiveness results using both sets of utility
scores (McSad and EQ-5D) separately.
Probabilistic sensitivity analysis
In order to characterize the uncertainty in the model
we undertook a probabilistic sensitivity analysis
using Monte Carlo simulation. We applied probability
distributions to each parameter which are summarized
in Tables 1 and 2 and depend on the nature of the par-
ameter (Briggs et al. 2006).
Probabilities were generally characterized by a
beta distribution which is deﬁned by two parameters,
alpha and beta representing the occurrence and
non-occurrence of an event, respectively. Using the
data derived from the RCT that compared ECT and
rTMS, we were able to construct relative risks for a ser-
ies of events in our model. The logarithmic transforma-
tions of these relative risks were modelled using a
normal distribution. Resource-use data inputs were
characterized using a gamma distribution, while uni-
form distributions were applied to unit costs par-
ameters; in both cases, we used upper and lower
limits of 20% around the mean values with the excep-
tion of the number of sessions of both ECT and rTMS
during continuation treatment for which we applied
a 50% variation given the reported variation across stu-
dies about these input values. We used beta distribu-
tions to characterize the uncertainty around the
utility values.
We applied 1000 simulations in the Monte Carlo
analysis. For each simulation we obtained the mean
cost and QALY of each alternative which we graphi-
cally represented in the cost-effectiveness plane.
These simulations were also used to compute the
CEAC, which represents the probability that each
alternative is cost-effective at different values of will-
ingness to pay per effectiveness unit.
Results
The results of the analysis are presented in Table 3. The
mean QALY value, using the utility weights as esti-
mated by Bennett et al. (2000) are 0.263, 0.214, and
0.178 for the strategies rTMS followed by ECT, ECT
alone, and rTMS alone, respectively. Using the utility
Table 3. Expected cost and QALY results
Cost (95% CI) QALY (95% CI)using McSad QALY (95% CI)using EQ-5D
ECT €16 690 0.2137 0.4253
rTMS €16 858 0.1783 0.3988
rTMS followed by ECT €20 279 0.2631 0.4598
Incremental
ECT v. rTMS €−168 (€−4065 to 4294) 0.0354 (−0.0319 to 0.0912) 0.0265 (−0.0279 to 0.07423)
rTMS + ECT v. ECT €3589 (€577 to 6664) 0.0494 (0.0183 to 0.1148) 0.0345 (−0.0094 to 0.1017)
ICER
ECT v. rTMS ECT alone dominates ECT alone dominates
rTMS + ECT v. ECT €72 668 €103 953
QALY, Quality adjusted life year; ECT, electroconvulsive therapy; rTMS, repetitive transcranial magnetic stimulation; ICER,
incremental cost-effectiveness ratio; CI, conﬁdence interval.
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scores reported in Mann et al. (2009) the QALYs for
these treatment strategies are 0.460, 0.425, and 0.399,
respectively. In both cases, rTMS + ECT achieved the
higher QALY value, followed by the ECT-alone option,
and last the rTMS-alone strategy. The mean cost over
the 12-month interval of rTMS followed by ECT,
ECT-alone, and rTMS-alone strategies are €20 279,
€16 690, and €16 858, respectively. Therefore the use
of ECT leads to the lowest estimated costs, while the
strategy of using both rTMS and ECT when the former
fails yields the largest mean costs.
Combining the differences in costs and in QALYs we
observed that the rTMS-alone strategy is dominated by
the ECT-alone strategy, irrespective of the source of
utility weights used, i.e. ECT alone leads to better
medical results and is cheaper than using rTMS
alone. On average, ECT yields to an effectiveness
gain of 0.035 or 0.0264 QALYs, depending on the util-
ity weights used, and is €168 less costly per patient in
the year under analysis. When comparing use of rTMS
followed by ECT v. ECT alone, we observed that the in-
cremental cost of providing both treatment options
when needed is €3589, while the incremental effec-
tiveness is between 0.035 and 0.049 QALYs. The
estimated incremental costs per QALY gained of the
strategy rTMS + ECT compared with ECT alone are
€72 668 and €103 953, which are in both cases consider-
ably higher than the reference willingness-to-pay
threshold recommended in this type of studies in
Spain and other countries.
Fig. 2 shows graphically the uncertainty with
respect to the estimated costs and QALYs related to
each strategy. The upper panels represent the pair
of mean cost and QALY values of each of the
Monte Carlo simulations for each of the three alterna-
tive strategies and under both sets of utility values.
We observe that there is a large degree of overlap-
ping between the strategies of providing ECT alone
and rTMS alone, although for a proportion of simula-
tions the ECT strategy is estimated to be more effec-
tive. The strategy of providing rTMS followed by
ECT when rTMS fails is both more effective and
more expensive in the majority of the simulation
results. The lower panels show the CEACs. At the ref-
erence threshold value of €30 000 per QALY, the
strategy with the highest probability of being cost-
effective is the ECT-alone option with a probability
of nearly 70% which is reduced to 63% when the
Fig. 2. Monte Carlo simulation and cost-effectiveness acceptability curves. QALY, quality adjusted life year; ECT,
electroconvulsive therapy; rTMS, repetitive transcranial magnetic stimulation.
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utility scores used are those reported in Mann et al.
(2009).
Discussion
Depression places a huge burden in society both in
terms of morbidity and mortality and also in terms
of economic costs. In Spain the direct medical costs
of depression and bipolar disorders have been esti-
mated as €648 million in 2002 (López Bastida &
Oliva Moreno, 2005). More recently and in Catalonia
alone (with a population share of over 15% of the
total Spanish population) the direct healthcare costs
of depression were estimated as €156 million in 2009
prices (Salvador-Carulla et al. 2011). These high levels
of public spending and the rising costs of treatments
have intensiﬁed the need for information on the cost-
effectiveness of interventions for depression (Barrett
et al. 2005).
Although there are effective treatments for de-
pression, such as antidepressant medication or psycho-
therapy, in severe cases ECT and rTMS can be
considered as ﬁrst- or second-line treatments. The
British NICE guideline considers the use of ECT for
the acute treatment of major depression that may in-
volve a threat to life, for those cases requiring a rapid
response, or when other treatments have failed
(National Collaborating Centre for Mental Health,
2010). Regarding the safety of this technique, damage
on several cognitive domains has been observed im-
mediately after the treatment (Carney et al. 2003;
Dunne & McLoughlin, 2012). Nevertheless, recovery of
damaged domains, even the improvement in several
domains in comparison to base values, is observed
after a few days. With regards to rTMS, the NICE guide-
line concludes that there is no evidence suggesting
major safety concerns, but there is uncertainty regarding
the procedure’s clinical efﬁcacy. In sum, ECT has been
found to be more effective on reducing depressive
symptoms than repetitive rTMS, but the risk of adverse
effects associated with rTMS is lower. This highlights
the need to compare these treatment options in terms
of the clinical effectiveness and potential side-effects,
and, importantly, in terms of their cost-effectiveness.
Published evidence on the cost-effectiveness of ECT
and rTMS is inconsistent. The conﬂicting conclusion in
Knapp et al. (2008) might be due to the fact that their
analysis was based on data from a single trial and
did not include all available evidence. By contrast,
the analysis by Kozel et al. (2004) can no longer be con-
sidered to be a complete picture of what is currently
known about the cost-effectiveness of ECT compared
to rTMS and hence requires updating with information
from more recent trials. The aim of this study was to
undertake an economic evaluation of the use of ECT
alone, rTMS alone, and rTMS followed by ECT in the
treatment of resistant severe depression based on all
available evidence.
Our results are in line with the results found in
Knapp et al. (2008). ECT alone was estimated to be
the strategy more likely to be cost-effective; rTMS
alone was found to be on average less effective and
more expensive than ECT alone. In our evaluation
we also compared ECT and rTMS alone with the
option of providing rTMS followed by ECT when
rTMS fails as in Kozel et al. (2004). Contrary to the
results reported in Kozel et al. (2004), and after ac-
counting for recent evidence, we found that this strat-
egy was not likely to be cost-effective at standard
values of willingness to pay per effectiveness unit.
Our study has a number of limitations. First, we
have focused on the NHS perspective in Spain and
thus we did not include patient and family costs nor
did we account for productivity losses related to the
condition. Labour productivity losses related to de-
pression are signiﬁcant and in Spain they were esti-
mated at €1685 million in 2002 (López Bastida &
Oliva, 2005). There is, however, controversy regarding
the need to account for productivity losses on cost-
effectiveness analysis, and the NICE guideline on tech-
nology appraisal explicitly indicates that productivity
costs should not be included in either the reference
or non-reference case of cost-effectiveness analyses
(NICE, 2013). Second, given the paucity of evidence
for longer periods, we considered a 12-month time hor-
izon in the evaluation which might not fully capture
the differences across strategies in the costs and effec-
tiveness related to the interventions. However, pre-
vious studies have found that the scores in the
HAMD are not different between intervention groups
after 6 months of treatment (Knapp et al. 2008),
which might suggest that the main differences are
likely to occur within the time-frame of our analysis.
Third, there might be other unmeasured factors that af-
fect patients’ experience in the use of these techniques,
such as fear or anxiety regarding the receipt of treat-
ment, and especially for ECT. Furthermore, while
there are a number of good quality studies on the effec-
tiveness of ECT v. rTMS in the literature, the model de-
veloped for this analysis required information for a
number of parameters which were not measured in
these comparative studies such as suicide rates and
the risk of discontinuation of treatment after remission
which were estimated from the richer literature on the
use of ECT. We also had to impose some assumptions
in the model parameters, such as using some health-
care resource-use information from the detailed de-
scription recorded alongside a RCT undertaken in the
UK, to which we applied unit costs related to the
Spanish context. There might be regional differences
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on how care is delivered and thus we ran a determinis-
tic sensitivity analysis to explore the impact of this as-
sumption. We found that applying 50% upper and
lower limits around each of the resource-use ﬁgures
reported in the UK study did not impact on our results
(see Table 4). The parameters that we found to have
some impact on the results were the ECT and rTMS
treatment costs, for which we found that in the case
of acute rTMS treatment costs was 50% lower (or
ECT costs 50% higher) while holding the remaining
parameters constant, then the incremental cost per
QALY gained of ECT alone compared to rTMS
would be around €40000 (Table 4). Finally, it is
worth mentioning that while in some cases we used
data from international studies, a series of input values
are speciﬁc to Spain, such as unit costs and some para-
meters on healthcare resource use. As a result, our con-
clusions might not be applicable to other healthcare
contexts.
This evaluation shows that ECT is likely to be the
most cost-effective option for the treatment of resistant
severe depression given the estimated lower effective-
ness of rTMS and the lack of evidence regarding cost
savings related to the use of rTMS. The evidence pro-
vided in this study will be useful to inform decision
makers considering information on relative effective-
ness and costs when facing the choice between these
alternative techniques.
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